ArticleFrontiers in immunology2026
IL18BP links antigen processing and presentation programs to a dendritic cell-enriched immunoregulatory state in colorectal cancer.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Antigen processing and presentation (APP) is required for tumor immune recognition, but its relationship with the immune landscape in colorectal cancer (CRC) remains incompletely defined. In this study, APP-related transcriptional programs were used as the starting point to identify immune-cell-associated biomarkers with prognostic and immunotherapeutic relevance in CRC. Methods: Six public CRC bulk cohorts were analyzed to define APP-related molecular states. Weighted gene co-expression network analysis and four machine-learning frameworks, including Boruta, LassoLR, Pamr, and XGBoost, were applied to prioritize genes linked to APP activity. Single-cell analysis was performed with an atlas of 121 samples and 169,427 cells to identify the cellular origin of the candidate gene. Immune infiltration, cancer-immunity-cycle activity, immune checkpoint blockade (ICB) response, predicted drug response, somatic mutation patterns, and Results: Two APP-associated patterns were identified and showed different survival outcomes and immune landscapes. Network- and machine-learning-based screening prioritized IL18BP as the main APP-associated candidate. Higher IL18BP expression was associated with longer survival and an immune-active phenotype, including stronger antigen-presentation signals, increased immune infiltration, checkpoint-related signatures, and cancer-immunity-cycle activation. Single-cell profiling showed that IL18BP was preferentially enriched in dendritic cells (DCs), linking the APP-derived bulk signature to a DC-centered immunoregulatory compartment. Across nine external ICB-treated cohorts, IL18BP showed response-classification performance. Drug-response prediction and somatic mutation analyses identified additional features associated with IL18BP-defined groups. In CRC cell lines, IL18BP knockdown increased proliferation, migration, and invasion. Conclusion: These findings identify IL18BP as a DC-enriched, APP-associated biomarker in CRC. By connecting APP programs in bulk tumors with DC-level expression patterns at single-cell resolution, this study positions IL18BP as an APP-associated marker of a DC-enriched immune state. These findings support further evaluation of IL18BP for prognostic and immunotherapy stratification in colorectal cancer but do not establish a causal APP-DC-IL18BP pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.